TB22
TB22 is a non-nucleoside inhibitor of DOT1LR231Q, possessing anticancer activity. TB22 inhibits the malignant phenotype of lung cancer cells carrying the R231Q mutation through the MAPK/ERK signaling pathway, and can be used for lung cancer research[1].
Product Specifications
UNSPSC
12352211
Target
Histone Methyltransferase
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tb22.html
Smiles
CC(C1=CC=C(C=C1)NC(NCCCN(CCCN2CCOCC2)CC3(O)CN(CC3)C4=NC(Cl)=NC5=C4C=CS5)=O)(C)C
Molecular Formula
C32H46ClN7O3S
Molecular Weight
644.27
References & Citations
[1]Tan Z, et al. Discovery of Novel Non-nucleoside DOT1LR231Q Inhibitors with Improved Pharmacokinetic Properties and Anti-lung Cancer Efficacy[J]. Journal of Medicinal Chemistry, 2024.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1134155-01 0.02 mg (E-Coli)
Recombinant Pseudomonas aeruginosa Thiazole synthase (thiG)
Ask
View Details 
MBS1134155-02 0.02 mg (Yeast)
Recombinant Pseudomonas aeruginosa Thiazole synthase (thiG)
Ask
View Details MBS1134155-03 0.1 mg (E-Coli)
Recombinant Pseudomonas aeruginosa Thiazole synthase (thiG)
Ask
View Details MBS1134155-04 0.1 mg (Yeast)
Recombinant Pseudomonas aeruginosa Thiazole synthase (thiG)
Ask
View Details MBS1134155-05 0.02 mg (Baculovirus)
Recombinant Pseudomonas aeruginosa Thiazole synthase (thiG)
Ask
View Details